4.6 Article

Acute coronary syndromes in young patients: Presentation, treatment and outcome

Journal

INTERNATIONAL JOURNAL OF CARDIOLOGY
Volume 148, Issue 3, Pages 300-304

Publisher

ELSEVIER IRELAND LTD
DOI: 10.1016/j.ijcard.2009.11.009

Keywords

Cohort studies; Myocardial ischemia; Coronary angiography

Funding

  1. Swiss Heart Foundation
  2. Abbott, Switzerland
  3. Astra-Zeneca, Switzerland
  4. Biotronik, Switzerland
  5. Bristol-Myers Squibb, Switzerland
  6. Essex/MSD, Switzerland
  7. GlaxoSmithKline, Switzerland
  8. Guidant, Switzerland
  9. INVATEC, Switzerland
  10. Johnson & Johnson - Cordis Division, Switzerland
  11. A Menarini, Switzerland
  12. Aventis, Switzerland
  13. Schering, Switzerland
  14. Servier, Switzerland
  15. SPSS, Switzerland
  16. St. Jude Medical, Switzerland
  17. Takeda Pharma, Switzerland
  18. Robert Bosch Foundation, Stuttgart, Germany

Ask authors/readers for more resources

Background: Acute coronary syndromes (ACS) in very young patients have been poorly described. We therefore evaluate ACS in patients aged 35 years and younger. Methods: In this prospective cohort study, 76 hospitals treating ACS in Switzerland enrolled 28,778 patients with ACS between January 1, 1997, and October 1, 2008. ACS definition included ST-segment elevation myocardial infarction (STEMI), non-ST-segment elevation myocardial infarction (NSTEMI), and unstable angina (UA). Results: 195 patients (0.7%) were 35 years old or younger. Compared to patients >35 years, these patients were more likely to present with chest pain (91.6% vs. 83.7%; P=0.003) and less likely to have heart failure (Killip class II to IV in 5.2% vs. 23.0%; P<0.001). STEMI was more prevalent in younger than in older patients (73.1% vs. 58.3%; P<0.001). Smoking, family history of CAD, and/or dyslipidemia were important cardiovascular risk factors in young patients (prevalence 77.2%, 55.0%, and 44.0%). The prevalence of overweight among young patients with ACS was high (57.8%). Cocaine abuse was associated with ACS in some young patients. Compared to older patients, young patients were more likely to receive early percutaneous coronary interventions and had better outcome with fewer major adverse cardiac events. Conclusions: Young patients with ACS differed from older patients in that the younger often presented with STEMI, received early aggressive treatment, and had favourable outcomes. Primary prevention of smoking, dyslipidemia and overweight should be more aggressively promoted in adolescence. (C) 2009 Elsevier Ireland Ltd. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available